Actinium Pharmaceuticals (NYSEAM:ATNM) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

ATNM Overzicht aandelen

Actinium Pharmaceuticals, Inc. ontwikkelt stralingsconjugaten op basis van antilichamen en andere gerichte radiotherapieën die bedoeld zijn om de resultaten te verbeteren voor mensen die falen op het gebied van bestaande oncologische therapieën.

Over het bedrijf

ATNM fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	2/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Trading at 95.2% below our estimate of its fair value

Revenue is forecast to grow 61.33% per year

Risicoanalyse

Makes less than USD$1m in revenue ($81K)

Highly volatile share price over the past 3 months

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 meer risico

Actinium Pharmaceuticals, Inc. Concurrenten

Homology Medicines

NasdaqGS:FIXX

US$54.3m

MediciNova

NasdaqGM:MNOV

US$103.0m

Entera Bio

NasdaqCM:ENTX

US$69.0m

RAPT Therapeutics

NasdaqGM:RAPT

US$70.2m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Actinium Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers	US$1.82
52 Week Hoogtepunt	US$10.24
52 Week Laag	US$1.33
Bèta	0.15
11 maand verandering	-8.54%
3 maanden verandering	-75.00%
1 Jaar Verandering	-68.29%
33 jaar verandering	-78.18%
5 jaar verandering	-69.82%
Verandering sinds IPO	-97.98%

Recent nieuws en updates

Recent updates

Actinium Pharmaceuticals (NYSEMKT:ATNM) Is In A Good Position To Deliver On Growth Plans

Dec 28

Rendement voor aandeelhouders

	ATNM	US Biotechs	US Markt
7D	0.6%	-0.2%	-0.4%
1Y	-68.3%	22.1%	34.1%

Rendement versus industrie: ATNM underperformed the US Biotechs industry which returned 21.7% over the past year.

Rendement versus markt: ATNM underperformed the US Market which returned 33.4% over the past year.

Prijsvolatiliteit

Is ATNM's price volatile compared to industry and market?
ATNM volatility
ATNM Average Weekly Movement	21.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: ATNM's share price has been volatile over the past 3 months.

Volatiliteit in de loop van de tijd: ATNM's weekly volatility has increased from 15% to 22% over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
n/a	49	Sandesh Seth	www.actiniumpharma.com

Actinium Pharmaceuticals, Inc. ontwikkelt antilichaam-stralingsconjugaten en andere gerichte radiotherapieën die bedoeld zijn om de resultaten te verbeteren voor mensen die falen op het gebied van bestaande oncologische therapieën. Iomab-B is een inductie- en conditioneringsmiddel voorafgaand aan beenmergtransplantatie bij patiënten met recidief en refractair acute myeloïde leukemie (r/r AML). Het bedrijf richt zich op de ontwikkeling van productkandidaat Actimab-A, een therapeutisch middel waarvan de potentiële activiteit bij r/r AML-patiënten is aangetoond.

Actinium Pharmaceuticals, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Actinium Pharmaceuticals zich tot de beurswaarde?
ATNM fundamentele statistieken
Marktkapitalisatie	US$58.57m
Inkomsten(TTM)	-US$42.62m
Inkomsten(TTM)	US$81.00k

700.0x

P/S-verhouding

-1.3x

Koers/Winstverhouding

Is ATNM overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
ATNM resultatenrekening (TTM)
Inkomsten	US$81.00k
Kosten van inkomsten	US$0
Brutowinst	US$81.00k
Overige uitgaven	US$42.70m
Inkomsten	-US$42.62m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.37
Brutomarge	100.00%
Nettowinstmarge	-52,620.99%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde ATNM op de lange termijn?

Bekijk historische prestaties en vergelijking

ATNM Overzicht aandelen

Beloningen

Risicoanalyse

Actinium Pharmaceuticals, Inc. Concurrenten

NasdaqGS:FIXX

US$54.3m

NasdaqGM:MNOV

US$103.0m

NasdaqCM:ENTX

US$69.0m

NasdaqGM:RAPT

US$70.2m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Recent updates

Price target decreased by 18% to US$19.56

No longer forecast to breakeven

Actinium Pharmaceuticals, Inc. Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S

Actinium Pharmaceuticals, Inc. Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index

Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial

Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial

Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern

Forecast breakeven date pushed back to 2026

Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting

Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy

Price target increased by 8.4% to US$25.36

Price target increased by 32% to US$23.40

Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition

Actinium Pharmaceuticals, Inc., Annual General Meeting, Nov 30, 2023

Consensus revenue estimates fall by 85%

Price target decreased by 25% to US$18.61

Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer

Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting

National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc

Price target decreased by 13% to US$24.78

Consensus EPS estimates fall by 10%

Price target decreased by 8.9% to US$27.41

Consensus revenue estimates decrease by 52%, EPS upgraded

Consensus revenue estimates increase by 13%

Price target increased by 15% to US$32.62

Actinium Pharmaceuticals, Inc. to Present Full Results from Pivotal Phase 3 Iomab-B SIERRA Trial on Investor Call Following the Late-Breaker Presentation at the 2023 Transplantation & Cellular Therapy Tandem Meetings

Forecast to breakeven in 2025

Actinium Highlights Survival Data in Relapsed/Refractory Aml Patients with Prior Venetoclax Treatment And/Or with A Tp53 Mutation from the Actimab-A Clag-M Combination Trial Oral Presentation At Ash

Consensus revenue estimates fall by 16%

Actinium Pharmaceuticals, Inc., Annual General Meeting, Dec 08, 2022

Consensus forecasts updated

Forecast to breakeven in 2024

Price target increased to US$28.43

Insufficient new directors

Actinium Pharmaceuticals, Inc. Provides Update on Iomab-B and the Pivotal Phase 3 Trial

Price target increased to US$27.23

Actinium Pharmaceuticals, Inc. Announces Positive Top-Line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. Announces Executive Changes

Actinium Pharmaceuticals, Inc. Announces Executive Appointments

Actinium Pharmaceuticals, Inc. Provides Topline Results for the Pivotal Phase 3 Sierra Trial for Iomab-B

No longer forecast to breakeven

Price target decreased to US$24.04

Consensus revenue estimates fall by 22%

Consensus forecasts updated

Consensus revenue estimates increase by 193%

Price target decreased to US$26.71

Insufficient new directors

Actinium Pharmaceuticals, Inc. Highlights Data from Full Patient Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B Was Presented in an Oral Presentation At the Upcoming Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR

Actinium Pharmaceuticals, Inc. Highlights Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy at AACR

Forecast to breakeven in 2024

Forecast to breakeven in 2023

Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with Clag-M for Patients with Relapsed or Refractory AML

Actinium Pharmaceuticals, Inc. Announces Positive Data from Fully Enrolled Pivotal Phase 3 SIERRA Trial of Iomab-B Presents at 63rd American Society of Hematology Annual Meeting and Exposition

Forecast to breakeven in 2023

Chief Medical Officer Mark Berger has left the company

Chief Medical Officer Mark Berger has left the company

Actinium Pharmaceuticals, Inc. Completes Enrollment in the Pivotal Phase 3 SIERRA Trial of Iomab-B